Immuron (IMRN) Gross Profit (2016 - 2024)
Immuron (IMRN) posted quarterly Gross Profit of -$1876473562.4 billion for Q4 2024, down 118737997098274.4% year-on-year from N/an in Q1 2024, and down 118737997098274.4% on a QoQ basis from $1.6 million in Q4 2023.
Immuron (IMRN) Gross Profit (2016 - 2024) Analysis & Trends
Immuron (IMRN) has reported Gross Profit for 9 consecutive years, with -$1876473562.4 billion the latest figure, recorded in Q4 2024.
- Quarterly Gross Profit fell 118737997098274.4% year-over-year to -$1876473562.4 billion in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$1876473562.4 billion (down 164177891047.62% YoY) and the FY2025 annual result came in at $3.4 million, up 42.8% from the prior year.
- Gross Profit declined to -$1876473562.4 billion in Q4 2024 per IMRN's latest filing, from $1.6 million in the prior quarter.
- Over the last five years, Gross Profit for IMRN reached as high as $1.1 billion in Q4 2021 and fell as low as -$1876473562.4 billion in Q4 2024.
- A 5-year average of -$312745593.5 billion and a median of $250219.7 in 2022 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2021 — Gross Profit surged 20644628.43% — and 2024, when it plunged 118737997098274.4%.
- Year by year, Gross Profit stood at $5526.2 in 2020, then jumped by 20644628.43% to $1.1 billion in 2021, then plunged by 99.96% to $427920.0 in 2022, then jumped by 269.31% to $1.6 million in 2023, then plunged by 118737997098274.4% to -$1876473562.4 billion in 2024.
- According to Business Quant data, Gross Profit over the past three periods registered -$1876473562.4 billion, $1.6 million, and $72519.4 for Q4 2024, Q4 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1,876,473,562.38 Bn |
| Dec 31, 2024 | -1,876,473,562.38 Bn |
| Dec 31, 2023 | 1.58 Mn |
| Dec 31, 2023 | 1.58 Mn |
| Jun 30, 2023 | 72,519.39 |
| Jun 30, 2023 | 72,519.39 |
| Dec 31, 2022 | 427,920.00 |
| Dec 31, 2022 | 427,920.00 |
| Dec 31, 2021 | 1.14 Bn |
| Dec 31, 2021 | 1.14 Bn |
| Dec 31, 2020 | 5,526.21 |
| Dec 31, 2020 | 5,526.21 |
| Dec 31, 2019 | 11,214.25 |
| Dec 31, 2019 | 11,214.25 |
| Dec 31, 2018 | 746,754.00 |
| Dec 31, 2018 | 746,754.00 |
| Dec 31, 2017 | 723,782.00 |
| Dec 31, 2017 | 723,782.00 |
| Dec 31, 2016 | 479,705.00 |
| Dec 31, 2016 | 479,705.00 |